Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026

Lighthouse Pharmaceuticals reported new Phase 2/3 GAIN trial analyses for atuzaginstat (a gingipain inhibitor targeting Porphyromonas gingivalis, Pg), stating it was associated with benefits across several neuropsychiatric outcomes. The release provides no specific effect sizes or endpoint percentages in the excerpt. Overall, the update is a modest positive catalyst for biotech sentiment but is unlikely to be broadly market-moving by itself.

Analysis

Lighthouse Pharmaceuticals reported new Phase 2/3 GAIN trial analyses for atuzaginstat (a gingipain inhibitor targeting Porphyromonas gingivalis, Pg), stating it was associated with benefits across several neuropsychiatric outcomes. The release provides no specific effect sizes or endpoint percentages in the excerpt. Overall, the update is a modest positive catalyst for biotech sentiment but is unlikely to be broadly market-moving by itself.